P1, N=41, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting | N=103 --> 41

The fully human monoclonal antibody targeting EpCAM, adecatumumab, was conjugated with the photosensitizer IR700 at different dye-antibody ratios (DAR2, DAR4, DAR7) and tested on OE19 cells and xenograft mouse models under near-infrared light irradiation...Notable EpCAM expression and homogeneity underpin EpCAM as a promising target for NIR-PIT in EGJ adenocarcinoma. The fully human anti-EpCAM antibody may be suitable for NIR-PIT in EGJ adenocarcinoma.

P1, N=168, Recruiting, BioAtla, Inc. | Trial completion date: Dec 2025 --> Sep 2028 | Trial primary completion date: Jun 2025 --> Sep 2028

P1/2, N=482, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting

The study demonstrates the efficacy, safety and feasibility of CATUVAB® for the re-infusion of autologous EC processed by a cell salvage device during high-blood-loss cancer surgeries. These promising results have the potential to re-define the intraoperative blood salvage protocols in cancer surgeries.

We first evaluated the target cell-killing efficacy of EpCAM-targeted NIR-PIT (EpCAM-NIR-PIT) using the antibody Edrecolomab in human breast and colon cancer models characterized by high EpCAM expression...Furthermore, mice that achieved CR demonstrated resistance to tumour rechallenge, indicating the establishment of long-term anticancer immunity. This study demonstrated that EpCAM-NIR-PIT, particularly when combined with immune-activating agents such as anti-PD-1, is a promising new approach for cancer treatment, inducing durable and systemic anticancer immunity.

P1/2, N=482, Not yet recruiting, BioNTech SE

P1/2, N=96, Recruiting, Wuhan YZY Biopharma Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Oct 2026 | Trial primary completion date: Jun 2024 --> Apr 2026

P3, N=312, Active, not recruiting, Wuhan YZY Biopharma Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Nov 2025

P2, N=115, Completed, Wuhan YZY Biopharma Co., Ltd. | Active, not recruiting --> Completed | N=80 --> 115 | Trial completion date: Dec 2024 --> Aug 2024

P1, N=35, Completed, Wuhan YZY Biopharma Co., Ltd. | Recruiting --> Completed

Of these studies, 21 publications were included for meta-analysis, focussing on four TCEs: catumaxomab, ertumaxomab, tebentafusb, and MDX-H210. Cytokine Release Syndrome (CRS) is potentially being under-reported due to challenges of differentiation of CRS from other inflammatory mediated constituent symptoms, although Fc-independent TCEs were linked to lower inflammatory toxicity. The review highlights TCE-dependent toxicity profiles and highlights key features that may ameliorate TCE tolerance.